<DOC>
	<DOCNO>NCT00464776</DOCNO>
	<brief_summary>This study ass optimal renoprotective dose Aliskiren hypertensive type 2 diabetes patient incipient overt nephropathy</brief_summary>
	<brief_title>Study Assess Optimal Renoprotective Dose Aliskiren Hypertensive Patients With Type 2 Diabetes Incipient Overt Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Male and/or female patient 3080 year age . Type 2 diabetes ( define use World Health Organization criterion ) Incipient overt nephropathy ( urinary albumin excretion 100 ≤ 2000 mg/day ) . Glomerular filtration rate ( GFR ) 40ml per minute To eligible randomization , patient must fulfill follow criterion : 1 . Patients ongoing hypertensive therapy must blood pressure ≥ 135/85 mm Hg low 170/105 mm Hg Visit 3 ( Day 1 , Period 1 ) AND patient must stable antihypertensive medication least 8 week prior Visit 2 ( Runin period ) 2 . Newly diagnose hypertensive patient must blood pressure ≥ 135/85 mm Hg low 170/105 mm Hg Visit 3 ( Day 1 , Period 1 ) Female patient must postmenopausal must bilateral oophorectomy must surgically sterilize hysterectomized least 6 month prior screen Oral body temperature within range 35.037.5 °C Able provide write informed consent prior study participation . Able communicate well investigator comply requirement study . Patients must willing medically able discontinue antihypertensive treatment medication prohibit study protocol . Patients must stable hypoglycemic medication least 8 week prior visit 1 ( Screening visit ) . Use prescription drug overthecounter ( OTC ) medication prohibit protocol . Severe Hypertension Grade 3 WHO classification Mean Sitting Diastolic Blood Pressure ( MSDBP ) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg ) Acetylsalicyclic acid ( ASA ) treatment &gt; 1g/day regular use Non steroidal antiinflammatory drug ( NSAIDs ) Kidney disease cause diabetes hypertension Serum potassium &lt; 3.5 &gt; 5.1 mEq/L GFR &lt; 40 ml/min/1.73m2 measure Modification Diet Renal Disease ( MDRD ) formula Serum albumin &lt; 2.0mg/dL History hypertensive encephalopathy cerebrovascular accident time prior Visit 1 Transient ischemic cerebral attack 6 month prior Visit 1 Current diagnosis heart failure New York Heart Association ( NYHA ) Class IIIV History myocardial infarction , unstable angina pectoris , coronary bypass surgery , percutaneous coronary intervention ( PCI ) 6 month prior Visit 1 Second third degree heart block without pacemaker Concurrent potentially life threaten arrhythmia symptomatic arrhythmia Clinically significant valvular heart disease Type 1 diabetes mellitus Uncontrolled Type II diabetes mellitus Hemoglobin subtype A1C ( HbA1C ) &gt; 11 % History malignancy include leukemia lymphoma ( basal cell skin carcinoma ) within past five year Pregnant nursing woman Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . Significant illness within two week prior dose . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug include , limited , follow : History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection Currently active previously active inflammatory bowel disease 12 month prior Visit 1 Currently active gastritis , duodenal gastric ulcer , gastrointestinal/rectal bleed 3 month prior Visit 1 . Any history pancreatic injury , pancreatitis evidence impair pancreatic function/injury indicate abnormal lipase amylase Evidence hepatic disease , history hepatic encephalopathy , history esophageal varix , history portocaval shunt Current treatment cholestyramine cholestipol resins History immunocompromise , include positive HIV test result . History positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month prior dose . Persons directly involved execution protocol . Any condition opinion investigator Novartis medical monitor would jeopardize evaluation efficacy safety History noncompliance medical regimen unwillingness comply study protocol Known suspect contraindication study medication , include history allergy ACE inhibitor and/or thiazide diuretic sulfonamide derive drug Any surgical medical condition , opinion investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study Patients previously participate Aliskiren study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Randomized</keyword>
	<keyword>double-blind</keyword>
	<keyword>cross-over</keyword>
	<keyword>4-period</keyword>
	<keyword>4 treatment</keyword>
	<keyword>within-subject placebo-controlled study</keyword>
	<keyword>ass optimal renoprotective dose Aliskiren</keyword>
	<keyword>hypertensive type 2 diabetes patient</keyword>
	<keyword>incipient overt nephropathy</keyword>
</DOC>